Clinical Trials in Brisbane, Australia
28 recruiting
Showing 1–20 of 90 trials
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled33 locationsNCT07258511
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled279 locationsNCT07218380
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled96 locationsNCT07190248
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Small Cell Lung Cancer
Merck Sharp & Dohme LLC262 enrolled45 locationsNCT06780137
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC780 enrolled257 locationsNCT06312137
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled232 locationsNCT06952504
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled125 locationsNCT06824467
Recruiting
Not Applicable
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Emphysema or COPDEmphysema, Pulmonary
Pulmonx Corporation200 enrolled36 locationsNCT06035120
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 2
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Novo Nordisk A/S200 enrolled92 locationsNCT06979375
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled239 locationsNCT06200207
Recruiting
Phase 3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled187 locationsNCT06901531
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176